ArticleJournal of diabetes investigation2019
Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology.
Article in Journal of diabetes investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center.Internal medicine (Tokyo, Japan) · 2023Article
- Association between dipeptidyl peptidase-4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5-year population-based cohort study using the Japanese National Database.Journal of diabetes investigation · 2022Article
- Severe edema and blood blisters of the lower extremities caused by sitagliptin, a dipeptidyl peptidase-4 inhibitor.Journal of general and family medicine · 2022Article
- Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence.World journal of diabetes · 2021Review
- New prospects for incretin-related drugs in the treatment of type 2 diabetes.Journal of diabetes investigation · 2021Article
- Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication.Clinical case reports · 2020Article
- Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.CEN case reports · 2020Article
- Ceritinib-associated hyperglycemia in the Japanese Adverse Drug Event Report Database.Journal of diabetes investigation · 2020Article
- The journey to understanding incretin systems: Theory, practice and more theory.Journal of diabetes investigation · 2019Article
- A Monocentric Retrospective Observational Study of Comorbidities in Patients Affected by Autoimmune Bullous Diseases.In vivo (Athens, Greece)Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is strongly suggested that dipeptidyl peptidase-4 inhibitors are associated with increased risk of bullous pemphigoid onset, especially in the elderly. Heightened clinical vigilance for bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor use is required in daily diabetes care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.